Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.31 - $59.39
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.35M
Market Cap
$5.92B
Enterprise Value$3.95B
Total Cash (Recent Filing)$858.13M
Total Debt (Recent Filing)$858.06M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Oct 30, 2025EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding119,657,160
10 Day Avg. Volume3,821,447
30 Day Avg. Volume2,346,219
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue46.01
Enterprise Value/Gross Profit-20.27
Enterprise Value/Ebitda-7.81
Forecast
1Y Price Target
$78.15Price Target Upside57.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceAficamten improved exercise capacity on the primary endpoint compared to metoprolol, showing significant clinical benefits.
Clinical TrialsAficamten gains potential for first-in-class status after the failure of the Phase 3 clinical trial for mavacamten in nHCM patients.
Regulatory MomentumAnalyst remains focused on the ongoing regulatory reviews for aficamten in obstructive hypertrophic cardiomyopathy, which is expected to drive further momentum for the stock.
Bears Say
Market ChallengesWith practical headwinds already slowing uptake in advanced patients, it's challenging to forecast much early-line use.
Population SizeWith nHCM accounting for a smaller population, the opportunity is unlikely to be much of a top-line driver.
Safety ConcernsODYSSEY revealed concerning safety signals for mavacamten in nonobstructive HCM, with LVEF <50% in 21.5% of patients, heart failure in 6.6%, and atrial tachyarrhythmias in 4.2%.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $59.39 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $5.92B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 07, 2025. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.43 by $0.31.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.58.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,657,160 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.43. Following the earnings report the stock price went down -3.234%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.15 (57.05% Upside)
$78.15 (57.05% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 118.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 33.3%
Last 30 Days ▲ 33.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.52%
12-Months-Change
Fundamentals
Return on Equity
435.49%
Trailing 12-Months
Asset Growth
-19.57%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and other therapeutics to treat debilitating diseases and medical conditions that affect muscle function. The company operates primarily in the sectors of neuromuscular diseases and cardiovascular diseases, with core products that include its lead drug candidates designed to enhance muscle contractility and improve overall muscle performance.
CYTK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant advancements in clinical trials, regulatory progress, and sales force readiness. However, these were countered by financial challenges, including increased expenses and a net loss, as well as a delayed PDUFA date impacting timelines for aficamten's approval.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$78.15
▲(57.05% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
0.80% Insiders
36.74% Mutual Funds
0.48% Other Institutional Investors
37.92% Public Companies and
Individual Investors